Vimarsana
Biggest News Aggregation in the World

Page 20 - Neil Kumar News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Neil Kumar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Neil Kumar Today - Breaking & Trending Today

Five Arkansas delegation members take fundraising lead - Vimarsana News

Five Arkansas delegation members take fundraising lead

Current members of Arkansas' congressional delegation are dominating on the fundraising front as the incumbents look to fend off GOP challengers in next month's primary election, according to Federal Election Commission filings.

BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis ... - Vimarsana News

BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis ...

- NT-proBNP, a biomarker of cardiac failure and independent predictor of mortality in ATTR-CM patients, was stable or improving throughout the study. At Month 30, median change from baseline in

BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - Vimarsana News

BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
SVB Leerink Research Analysts Increase Earnings Estimates for BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Vimarsana News

SVB Leerink Research Analysts Increase Earnings Estimates for BridgeBio Pharma, Inc. (NASDAQ:BBIO)

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) – Investment analysts at SVB Leerink increased their Q1 2022 earnings estimates for shares of BridgeBio Pharma in a research report issued on Tuesday, March 8th. SVB Leerink analyst M. Foroohar now anticipates that the company will post earnings of ($1.11) per share for the quarter, up from […]

Helsinn, BridgeBio update infigratinib collaboration for oncology indications - Vimarsana News

Helsinn, BridgeBio update infigratinib collaboration for oncology indications

Helsinn has announced an update to its existing collaboration with BridgeBio to develop, produce and commercialise infigratinib for oncology indications